These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Characterization of insulin-like growth factor II binding to human fibroblast monolayer cultures.
    Author: Thorsson AV, Hintz RL, Enberg G, Hall K.
    Journal: J Clin Endocrinol Metab; 1985 Feb; 60(2):387-91. PubMed ID: 2981246.
    Abstract:
    Two major somatomedin peptides have been isolated from human plasma, somatomedin-C/insulin-like growth factor I (SMC/IGF-I) and insulin-like growth factor II (IGF-II). Also, two types of SM/IGF receptors have been defined. Type I receptors have a higher affinity for SMC/IGF-I than IGF-II, and insulin binds to this receptor at high concentrations. Type II receptors have a higher affinity for IGF-II than SMC/IGF-I, and insulin does not bind to this receptor site. In this study, we characterized the binding of IGF-II to human monolayer fibroblast cultures, and the affinity and specificity of this binding. We also compared the binding of IGF-II to the binding of insulin and SMC/IGF-I to these cells. The receptors for IGF-II on normal human fibroblast monolayers fit the criteria for type II SM/IGF receptors, and there were more type II receptors on these cells than either insulin receptors or type I SM/IGF receptors. The type II receptors on human fibroblasts did not demonstrate autoregulation by homologous hormone, unlike the type I SM/IGF and insulin receptors. In addition, they were not changed by acute or chronic exposure to insulin. It is so far unclear what biological function IGF-II plays in vivo. This human fibroblast system will be a valuable experimental model for the study of IGF-II receptors and their relationship to the biological actions of IGF-II.
    [Abstract] [Full Text] [Related] [New Search]